Second-order morphometric similarity networks predict response to transcutaneous auricular vagus nerve stimulation in major depressive disorder: a two-center study - Report - MDSpire
Advertisement
Second-order morphometric similarity networks predict response to transcutaneous auricular vagus nerve stimulation in major depressive disorder: a two-center study
Predictive Value of Second-Order Morphometric Similarity Networks for Treatment Response to Transcutaneous Auricular Vagus Nerve Stimulation in Major Depressive Disorder
Overview
This study investigates the predictive capability of second-order morphometric similarity networks (MSN-II) for treatment response to transcutaneous auricular vagus nerve stimulation (taVNS) in patients with major depressive disorder (MDD). Findings indicate that MSN-II features can predict treatment outcomes, particularly highlighting the left orbitofrontal cortex as a key biomarker.
Background
Major depressive disorder (MDD) is a significant public health issue, with many patients not responding adequately to standard treatments. Non-invasive neuromodulation therapies like transcutaneous auricular vagus nerve stimulation (taVNS) are being explored as potential alternatives. Identifying reliable predictors of treatment response is crucial.
Data Highlights
Measure
Performance
MSN-II AUC (Training)
0.792 ± 0.158
MSN-II AUC (External Validation)
0.856 (95% CI: 0.693–0.978)
MSN-I AUC (External Validation)
0.804
Baseline MSN-II in L_OFC_A13 (Non-responders)
P = 0.021
Post-treatment MSN-II Decrease (Non-responders)
P < 0.001
Time × Group Interaction
P = 0.005
Key Findings
MSN-II demonstrated significant training performance with an AUC of 0.792.
External validation of MSN-II showed an AUC of 0.856, indicating strong predictive capability.
The left orbitofrontal cortex area 13 (L_OFC_A13) was identified as the strongest predictor of treatment response.
Non-responders exhibited higher baseline MSN-II in L_OFC_A13 compared to responders.
Post-treatment decreases in MSN-II were significant in non-responders, while responders showed stability.
Clinical Implications
MSN-II features, particularly from limbic regions, may serve as biomarkers for predicting treatment response to taVNS in MDD.
Conclusion
MSN-II offers an approach for predicting treatment outcomes in MDD patients undergoing taVNS, with specific emphasis on the left orbitofrontal cortex as a key biomarker.
